A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients.
DNA methylation
cell-free DNA
colorectal cancer
homocysteine
therapeutic response
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Mar 2022
29 Mar 2022
Historique:
received:
01
03
2022
revised:
25
03
2022
accepted:
28
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Monitoring the therapeutic response of colorectal cancer (CRC) patients is crucial to determine treatment strategies; therefore, we constructed a liquid biopsy-based approach for tracking tumor dynamics in non-metastatic (nmCRC) and metastatic (mCRC) patients (n = 55). Serial blood collections were performed during chemotherapy for measuring the amount and the global methylation pattern of cell-free DNA (cfDNA), the promoter methylation of SFRP2 and SDC2 genes, and the plasma homocysteine level. The average cfDNA amount was higher (p < 0.05) in nmCRC patients with recurrent cancer (30.4 ± 17.6 ng) and mCRC patients with progressive disease (PD) (44.3 ± 34.5 ng) compared to individuals with remission (13.2 ± 10.0 ng) or stable disease (12.5 ± 3.4 ng). More than 10% elevation of cfDNA from first to last sample collection was detected in all recurrent cases and 92% of PD patients, while a decrease was observed in most patients with remission. Global methylation level changes indicated a decline (75.5 ± 3.4% vs. 68.2 ± 8.4%), while the promoter methylation of SFRP2 and SDC2 and homocysteine level (10.9 ± 3.4 µmol/L vs. 13.7 ± 4.3 µmol/L) presented an increase in PD patients. In contrast, we found exact opposite changes in remission cases. Our study offers a more precise blood-based approach to monitor the treatment response to different chemotherapies than the currently used markers.
Identifiants
pubmed: 35409133
pii: ijms23073774
doi: 10.3390/ijms23073774
pmc: PMC8998310
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Homocysteine
0LVT1QZ0BA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hungarian National Research, Development and Innovation Office (NKFIH)
ID : NVKP_16-1-2016-0004
Organisme : Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary
ID : 0
Références
Int J Cancer. 2017 Apr 15;140(8):1888-1898
pubmed: 27943272
Oncogene. 2017 Aug 31;36(35):5035-5044
pubmed: 28459462
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Oncogene. 2017 Jun 15;36(24):3359-3374
pubmed: 28092669
Oncotarget. 2017 Feb 14;8(7):11906-11916
pubmed: 28060757
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
JAMA Oncol. 2019 Aug 1;5(8):1124-1131
pubmed: 31070691
Biomed Res Int. 2020 Mar 9;2020:6843180
pubmed: 32258135
Clin Chim Acta. 2018 Dec;487:107-111
pubmed: 30240586
Exp Mol Med. 2019 Feb 21;51(2):1-13
pubmed: 30804341
Front Oncol. 2020 Jul 16;10:1115
pubmed: 32766143
Anticancer Res. 2005 Jul-Aug;25(4):2627-30
pubmed: 16080503
Orv Hetil. 2007 Dec 30;148(52):2469-76
pubmed: 18079094
Genome Med. 2019 Mar 29;11(1):20
pubmed: 30925887
Int J Cancer. 2002 Aug 10;100(5):542-8
pubmed: 12124803
Yonsei Med J. 2017 Sep;58(5):918-924
pubmed: 28792134
Clin Chim Acta. 2019 Jan;488:209-214
pubmed: 30445031
J Cancer. 2021 Apr 30;12(12):3678-3685
pubmed: 33995643
Front Genet. 2019 Nov 14;10:1150
pubmed: 31803237
DNA Cell Biol. 2007 Aug;26(8):603-11
pubmed: 17688412
Ageing Res Rev. 2019 Jan;49:144-164
pubmed: 30391754
PLoS One. 2017 Mar 22;12(3):e0174308
pubmed: 28328955
Gut. 2018 Nov;67(11):1995-2005
pubmed: 28982739
Nucleic Acids Res. 2005 Jan 13;33(1):e9
pubmed: 15653630
Clin Chem. 2009 Jul;55(7):1337-46
pubmed: 19406918
Orv Hetil. 2019 Jul;160(30):1167-1177
pubmed: 31327245
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Biotechnol. 2010 Oct;28(10):1057-68
pubmed: 20944598
World J Surg. 2004 Jul;28(7):721-6
pubmed: 15185002
World J Gastroenterol. 2015 Mar 7;21(9):2629-37
pubmed: 25759530
Thromb Res. 2021 Jan;197:36-43
pubmed: 33166900
Am J Clin Pathol. 2011 Feb;135(2):264-70
pubmed: 21228367
Cancer Discov. 2014 Nov;4(11):1269-80
pubmed: 25293556
Gastroenterology. 2003 May;124(5):1240-8
pubmed: 12730865
Expert Rev Mol Diagn. 2019 Jun;19(6):477-498
pubmed: 31046485
Mol Genet Metab. 2014 Dec;113(4):243-52
pubmed: 25456744
Mol Oncol. 2016 Dec;10(10):1575-1584
pubmed: 28949453
Genome Res. 2012 Feb;22(2):271-82
pubmed: 21659424
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Cells. 2020 Aug 09;9(8):
pubmed: 32784836
Ann Oncol. 2018 Jan 1;29(1):112-118
pubmed: 28950295
Int J Cancer. 2021 Apr 1;148(7):1665-1675
pubmed: 33320961
Eur J Nutr. 2016 Aug;55(5):1863-73
pubmed: 26293976
Jpn J Clin Oncol. 2000 Jan;30(1):12-6
pubmed: 10770562
Cancer Cell. 2019 Oct 14;36(4):350-368
pubmed: 31614115
J Mol Biol. 2018 Jul 6;430(14):2051-2065
pubmed: 29758262
Ann Oncol. 2001 Feb;12(2):221-6
pubmed: 11300328
PLoS One. 2011 Apr 14;6(4):e18884
pubmed: 21533144
Acta Oncol. 2017 Jan;56(1):7-16
pubmed: 28010185
Curr Med Chem. 2017;24(15):1537-1557
pubmed: 28079003
J BUON. 2013 Apr-Jun;18(2):391-7
pubmed: 23818351
Gut. 2003 Jan;52(1):101-8
pubmed: 12477769
Cancers (Basel). 2016 Aug 31;8(9):
pubmed: 27589804
Dig Dis. 2012;30(3):310-5
pubmed: 22722557
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Trends Cancer. 2017 Oct;3(10):698-712
pubmed: 28958388
Clin Orthop Relat Res. 2014 Dec;472(12):3665-73
pubmed: 24664197
Diabetol Metab Syndr. 2017 Mar 21;9:19
pubmed: 28331553
Chin Med J (Engl). 2017 Aug 20;130(16):1980-1986
pubmed: 28776552
Ann Oncol. 2017 Jun 01;28(6):1325-1332
pubmed: 28419195
Epigenetics. 2017 Sep;12(9):751-763
pubmed: 28753106
J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8
pubmed: 19033568
Int J Mol Sci. 2020 Oct 29;21(21):
pubmed: 33137955
Cancer. 2011 May 1;117(9):1847-54
pubmed: 21509761
Clin Biochem. 2013 Jan;46(1-2):64-9
pubmed: 22975639
Ann Surg Oncol. 2014 Dec;21 Suppl 4:S680-6
pubmed: 24841357
J Biol Chem. 2000 Sep 22;275(38):29318-23
pubmed: 10884384